Literature DB >> 9453361

Trends in hypertension prevalence, treatment, and control: in a well-defined older population.

W H Barker1, J P Mullooly, K L Linton.   

Abstract

To assess medical attention focused on hypertension (HBP) in the elderly, this study examines trends in HBP prevalence, treatment, and control status in a defined population of persons > or = 65 years of age enrolled in a large HMO. Random samples of approximately 400 persons were drawn for the years 1967, 1974, 1981, and 1988. First recorded ambulatory pressures, available on over 90% of subjects in each period, were obtained from medical records. Prevalence of HBP (SBP > or = 160 and/or DBP > or = 95, and/or taking anti-HBP drugs) ranged between 44% to 53%. Proportion with HBP on treatment increased from 25% in 1967 to 60% in 1988 (P<.001); proportion on treatment and controlled (SBP < 160, DBP < 95) increased from 8% to 34% (P<.001). Mean population SBP declined from 155.2 in 1967 to 144.0 in 1988 (P<.001); mean DBP declined from 85.2 to 81.2 (P<.001). Proportion with isolated systolic hypertension (ISH) (SBP > or = 160, DBP < 90) remained unchanged at 12% to 14%. Use of diuretics and adrenergic antagonist agents declined while use of beta blockers and newer classes of anti-HBP drugs increased significantly among treated hypertensives in the 1980s. These findings parallel HBP trends in younger adults from National Health Survey data though we find evidence of a substantial gap in addressing the problem in the elderly, who constitute the population at greatest risk of cardiovascular complications of HBP.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9453361     DOI: 10.1161/01.hyp.31.1.552

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  7 in total

1.  Ethics in public health research: changing patterns of mortality among American Indians.

Authors:  Stephen J Kunitz
Journal:  Am J Public Health       Date:  2008-01-30       Impact factor: 9.308

2.  Cost sharing and the initiation of drug therapy for the chronically ill.

Authors:  Matthew D Solomon; Dana P Goldman; Geoffrey F Joyce; José J Escarce
Journal:  Arch Intern Med       Date:  2009-04-27

3.  Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study.

Authors:  Kaycee M Sink; Xiaoyan Leng; Jeff Williamson; Stephen B Kritchevsky; Kristine Yaffe; Lewis Kuller; Sevil Yasar; Hal Atkinson; Mike Robbins; Bruce Psaty; David C Goff
Journal:  Arch Intern Med       Date:  2009-07-13

4.  The impact of a 6-year comprehensive community trial on the awareness, treatment and control rates of hypertension in Iran: experiences from the Isfahan healthy heart program.

Authors:  Alireza Khosravi; Gilda Kiani Mehr; Roya Kelishadi; Shahin Shirani; Mojgan Gharipour; Aliakbar Tavassoli; Fatemeh Noori; Nizal Sarrafzadegan
Journal:  BMC Cardiovasc Disord       Date:  2010-12-21       Impact factor: 2.298

5.  Prevalence, prescribing and barriers to effective management of hypertension in older populations: a narrative review.

Authors:  Tariq M Alhawassi; Ines Krass; Lisa G Pont
Journal:  J Pharm Policy Pract       Date:  2015-10-14

6.  Prevalence, awareness, treatment, and control of hypertension: United States National Health and Nutrition Examination Survey 2001-2002.

Authors:  Bernard M Y Cheung; Kwok Leung Ong; Yu Bun Man; Karen S L Lam; Chu-Pak Lau
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-02       Impact factor: 3.738

7.  Socioeconomic characteristics and controlled hypertension: Evidence from Isfahan Healthy Heart Program.

Authors:  Mojgan Gharipour; Alireza Khosravi; Masoumeh Sadeghi; Hamidreza Roohafza; Mohammad Hashemi; Nizal Sarrafzadegan
Journal:  ARYA Atheroscler       Date:  2013-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.